中投顧問重磅推出產業研究大腦,是"產業研究的數字化高效工具",歡迎試用體驗! | ||||
---|---|---|---|---|
產品名稱 | 目標用戶 | 核心功能定位 | 產品介紹 | 試用申請 |
產業研究大腦 | 政府、企業內關注產業發展的領導及工作人員 | 產業研究工作的一站式解決方案 | 詳情 > | 申請 > |
聯系電話: 400 008 0586; 0755-82571568
微信掃碼:
1.EXECUTIVESUMMARY
·ExecutiveSummary
2.MARKETINTRODUCTION
·ResearchScopeandMethodology
ScopeandSegmentation
ResearchMethodology
·BloodCancerOverview
BloodCancerBiology
BloodCancerDefinitions
·MultipleMyelomaOverview
Etiology
StagingandPrognosticFactors
TreatmentOverview
·PatientForecasts
Prevalence
Incidence
Mortality
Staging
·GeneralMarketTrends
IndustryChallengesandStrategies
MarketDrivers
3.PRODUCTANDPIPELINEANALYSIS
·ApprovedProductAnalysis
ChemotherapyProductAnalysis
SteroidProductAnalysis
InterferonProductAnalysis
ImmunomodulatoryProductAnalysis
·PipelineAnalysis
ChemotherapyPipelineAnalysis
TargetedTherapyLateStagePipelineAnalysis
TargetedTherapyEarlyStagePipelineAnalysis
SupportiveProductPipeline
4.COMPETITIVEANALYSIS
·Introduction
TreatmentTrends
MarketEngineeringMeasurements
CommonDrugRegimens
DrugPrices
·MarketRevenueForecasts
TotalMarketRevenueForecasts
First-lineHSCTEligibleRevenueForecasts
First-lineHSCTNon-EligibleRevenueForecasts
Second-lineRevenueForecasts
Third-line+RevenueForecasts
MarketShareAnalysis
·ProductRevenueForecasts
Alkeran
Doxil
Revlimid
Thalomid
Velcade
Tanespimycin
ZIO-101
Perifosine
5.APPENDIX
·DecisionSupportDatabases
Physicians
GovernmentHealthcareExpenditure
PrivateHealthcareExpenditure
PharmaceuticalR&DExpenditure
PercentPharmaceuticalR&DExpenditure
The U.S. Multiple Myeloma Market is a rapidly progressing field that is set to generate over $3 billion in revenue in the coming years. The market has witnessed unprecedented growth with the launch of three new drugs. The dynamics of this market are changing rapidly and the forecast through 2013 highlights the major changes. This study includes patient forecasts, pipeline analysis and individual product revenue forecasts.